Catasys, Inc. (NASDAQ:CATS) has been given an average broker rating score of 2.00 (Buy) from the one brokers that cover the company, Zacks Investment Research reports. One investment analyst has rated the stock with a buy rating. Catasys’ rating score has declined by 33.3% from 90 days ago as a result of a number of analysts’ ratings changes.

Analysts have set a 12 month consensus price objective of $5.30 for the company and are expecting that the company will post ($0.09) EPS for the current quarter, according to Zacks. Zacks has also given Catasys an industry rank of 168 out of 265 based on the ratings given to its competitors.

Several analysts have recently weighed in on the company. Zacks Investment Research raised Catasys from a “sell” rating to a “hold” rating in a report on Thursday, February 8th. ValuEngine lowered Catasys from a “hold” rating to a “sell” rating in a report on Saturday, October 21st.

Shares of Catasys (CATS) opened at $4.32 on Thursday. Catasys has a fifty-two week low of $3.30 and a fifty-two week high of $14.00.

A hedge fund recently bought a new stake in Catasys stock. Weber Alan W purchased a new stake in Catasys, Inc. (NASDAQ:CATS) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 108,165 shares of the company’s stock, valued at approximately $406,000. Weber Alan W owned approximately 0.68% of Catasys at the end of the most recent reporting period. 5.88% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: This story was first published by Community Financial News and is owned by of Community Financial News. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright & trademark law. The original version of this story can be viewed at

About Catasys

Catasys, Inc provides data analytics based specialized behavioral health management and integrated treatment services to health plans and other third party payors. It offers OnTrak solution to improve treatment outcomes and lower the utilization of medical and behavioral health plan services. The company’s OnTrak solution includes medical and psychosocial interventions; and a proprietary Web based clinical information platform and database, psychosocial programs, and integrated care coaching services.

Get a free copy of the Zacks research report on Catasys (CATS)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Catasys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catasys and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit